Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study

The Lancet 2026

View at publisher
Authors: M Lia Palomba, Stephen J Schuster, Reem Karmali, Alan P Skarbnik, Jeremy Abramson, Kirit Ardeshna, Peter Borchmann, Brian T Hill, Alejandro Martin García-Sancho, Gianpaolo Marcacci, Aaron P. Rapoport, Guillaume Cartron
+18 more Isabelle Fleury, Koji Izutsu, Manali Kamdar, Stephan Mielke, Anna Maria Barbui, Juan Luis Reguera Ortega, Loretta J Nastoupil, Sairah Ahmed, Merav Bar, Lizbeth Diaz, Ulrika Furustrand, Victoria Diab, Min Vedal, Ariel Avilion, Jinender Kumar, Rina Nishii, Silvia Colicino, Franck Morschhauser
DOI: 10.1016/s0140-6736(25)02435-3
Cited by: 9
References: 34

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment CNS Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10532
Pages
963–975
Publication date
13 February 2026
Language
EN